MissionIR would like to highlight
Actinium Pharmaceuticals, Inc. (
NASDAQ: ATNM), a biopharmaceutical company with a proprietary platform that combines the precision targeting of monoclonal antibodies with the killing power of alpha and beta radioisotopes, the former being the most potent cancer killing agents in existence. Leveraging this platform and its ties with leading cancer institutions such as Sloan-Kettering (its largest shareholder), MD Anderson, Fred Hutchison, and Johns Hopkins, the company is focused on developing drugs for underserved cancers with no approved drugs which have multi-billion dollar market potential.
In the company’s news,
Actinium announced that it has engaged the investor relations services of MissionIR. Through its network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital as well as improve shareholder value.
“Actinium is wrapping up a year of tremendous progress in the development of its cancer treatment candidates, and is on the cusp of initiating additional clinical trials,” stated Sherri Franklin, Director of Marketing at MissionIR. “MissionIR is pleased to partner with the Company as it starts off a new year of advances with a firm stance and high potential in the biotech industry.”
“We’re moving closer to the commercialization of our cancer drugs, and want to increase visibility in the investment community and enhance communication with our existing shareholders along the way,” Dr. Kaushik J. Dave, President and CEO of Actinium, stated. “Engaging a full-service investor relations firm will help us develop and implement a strategic investor relations campaign to reach this goal. MissionIR is providing a much-needed service in the small-cap markets.”
Actinium is a New York-based pharmaceuticals company that is developing innovative immunotherapeutic solutions for treatment of advanced cancers. Specifically, the company harnesses its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals, in association with monoclonal antibodies, for development of alpha particle immunotherapeutics.
Actinium intends to develop its cancer treatment products through clinical trials and then intends to partner each drug for completion of development and commercialization with an appropriate third party. In working toward this objective, the company aims to increase brand awareness.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
